Dr. Reddy's Laboratories Limited (DRREDDY) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Dr. Reddy's Laboratories enters its Q1 FY27 results facing a significant operational headwind following the July 2026 disclosure of a quality-related supply halt for its semaglutide portfolio. Investors will be looking for the financial impact of this disruption, specifically the expected inventory write-down, alongside the company's progress toward its 25% EBITDA margin target.

Dr. Reddy's Laboratories Limited Q1 Results Date and Time

The board meeting is scheduled for July 22, 2026, to consider the audited financial results.

What to expect from Dr. Reddy's Laboratories Limited's Q1 FY27 results

Dr. Reddy's is expected to report a revenue decline YoY due to the ongoing lenalidomide base effect, though the India business likely sustained its high-teens growth momentum supported by a 10.3%–12.1% IPM market backdrop in April and May 2026. The Q1 P&L will be impacted by a semaglutide inventory write-down following the July 9, 2026, quality disclosure, which management has already flagged as a downside to the FY27 volume target of 12 million pens. Despite these headwinds, the company benefits from a tailwind in its North American segment due to the USD/INR exchange rate, which averaged approximately 95/USD during the quarter. Management remains committed to a 25% EBITDA margin target by FY27, and the upcoming call will focus on the underlying margin trajectory excluding the one-time write-down charge. The recent June 13, 2026, launch of Bosutinib with first-to-market exclusivity is expected to provide a new revenue stream to offset competitive pressures in the US generics market.

Key Things To Watch

Semaglutide quality issue impact: The July 2026 quality issue is the primary near-term risk to growth.

• Quantum of the inventory write-down to be booked in Q1 FY27
• Revised FY27 volume guidance of 6-7 million pens versus the original 12 million target
• Progress on scale-up resolution and supply resumption timeline expected by October 2026

Margin trajectory and cost control: Monitoring the path toward the 25% FY27 EBITDA margin goal.

• Underlying EBITDA margin recovery from the 19.5% base level seen in Q4 FY26
• Nominal SG&A spending trends to confirm if management's flat-cost guidance is on track
• PSAI gross margin sustainability within the 20-25% guided range

Revenue growth drivers: Assessing the performance of key business segments.

• India revenue growth trajectory relative to the 15-16% sustainable guidance
• Initial sales contribution from the Bosutinib launch (first-to-market exclusivity)
• Impact of USD/INR depreciation (approx. 95/USD) on reported North American revenue

Biosimilar and pipeline progress: Updates on critical long-term growth catalysts.

• Abatacept BLA review status with the USFDA
• Remediation progress for the Bachupally facility regarding Rituximab